Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results
May 05, 2020 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Announces Closing of $20 Million Public Offering
April 24, 2020 16:05 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 24, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING
April 21, 2020 08:27 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease
April 20, 2020 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J. and DUNDEE, United Kingdom, April 20, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical...
Cyclacel Announces Reverse Stock Split
April 14, 2020 12:30 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 14, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
February 26, 2020 16:05 ET
|
Cyclacel
– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib-venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – ...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results
February 19, 2020 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference
February 03, 2020 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
January 13, 2020 07:00 ET
|
Cyclacel
– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML/MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. ...
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco
January 06, 2020 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...